No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Contract research organisation Hvivo said on Monday that it has signed a £2.0m contract with a new biopharmaceutical client to complete the final stage of a characterisation study ahead of future hMPV human challenge trials.
Hvivo said the contract, which follows the success of its pilot human metapneumovirus characterisation trial, will see the firm aim to expand its dataset by enrolling additional healthy volunteers, further strengthening the model and ensuring "robust powering" for future hMPV HCTs.
The AIM-listed group stated the final phase of the study was expected to commence in H125, with revenues being recognised in 2025.
Chief executive Yamin Khan said: "We are pleased to have secured this £2.0m contract with a new biopharmaceutical client so soon after the successful pilot hMPV characterisation study. This underscores the significant value HCTs can bring in providing rapid, high-quality efficacy data to support vaccine and therapeutic development. hMPV currently has no approved vaccine or therapeutic on the market, and Hvivo is proud to lead the charge in helping our client bring medicines to the patients."
As of 1140 GMT, Hvivo shares were down 0.33% at 17.94p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
